Brit J Surg:肝细胞癌患者经动脉化疗栓塞术后的肝移植结局

2020-03-29 MedSci原创 MedSci原创

肝移植前给予HCC患者TACE治疗,对术后并发症、患者死亡或移植失败均无影响。

肝细胞癌(HCC)患者等待肝移植时,接受经动脉化疗栓塞术(TACE)的治疗已经非常广泛,尽管目前还没有证据表明它能改善患者预后,且对并发症存在着担忧。近日,外科疾病领域权威杂志British Journal of Surgery上发表了一篇研究文章,该研究旨在评估TACE对移植后结局的影响。

研究人员对在英国接受肝移植的HCC患者进行了识别,并根据他们在2006年至2016年期间是否接受了TACE进行了分层。在调整供体和受体特征后,Cox回归方法用于评估移植后死亡和移植失败的风险比(HRs)。

在968例患者中,385例(39.8%)患者接受了TACE治疗。在接受或未接受TACE治疗的患者中,移植术后5年的患者存活率相似:分别为75.2 (95%CI为68.8至80.5)和75.0(70.5至78.8)。在调整供体和受体特征后,死亡率(HR为0.96,95%CI为0.67到1.38,P=0.821)或移植失败(HR为1.01,0.73至1.40;P=0.964)无差异。TACE治疗次数(2次或2次以上 vs. 1次: HR为0.97,0.61至1.55;P = 0.903)或移植后死亡时间(90天内或90天后;P=0.291)并没有改变患者结局。在接受或未接受TACE治疗的患者中,肝动脉血栓形成的发生率较低(分别为1.3%和2.4%;P=0.235)。

由此可见,肝移植前给予HCC患者TACE治疗,对术后并发症、患者死亡或移植失败均无影响。

原始出处:

D. Wallace.Liver transplantation outcomes after transarterial chemotherapy for hepatocellular carcinoma.British Journal of Surgery.2020. https://doi.org/10.1002/bjs.11559

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1984599, encodeId=a4011984599fc, content=<a href='/topic/show?id=40d93356656' target=_blank style='color:#2F92EE;'>#化疗栓塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33566, encryptionId=40d93356656, topicName=化疗栓塞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Sat Aug 22 06:13:52 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803299, encodeId=08711803299a7, content=<a href='/topic/show?id=e503e52136a' target=_blank style='color:#2F92EE;'>#移植结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75213, encryptionId=e503e52136a, topicName=移植结局)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Thu Jun 11 00:13:52 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978961, encodeId=9c6f19e8961a2, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Jun 19 16:13:52 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863487, encodeId=6e9c186348e4a, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jan 21 08:13:52 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381168, encodeId=323c381168d1, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Tue Mar 31 00:14:10 CST 2020, time=2020-03-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1984599, encodeId=a4011984599fc, content=<a href='/topic/show?id=40d93356656' target=_blank style='color:#2F92EE;'>#化疗栓塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33566, encryptionId=40d93356656, topicName=化疗栓塞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Sat Aug 22 06:13:52 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803299, encodeId=08711803299a7, content=<a href='/topic/show?id=e503e52136a' target=_blank style='color:#2F92EE;'>#移植结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75213, encryptionId=e503e52136a, topicName=移植结局)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Thu Jun 11 00:13:52 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978961, encodeId=9c6f19e8961a2, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Jun 19 16:13:52 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863487, encodeId=6e9c186348e4a, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jan 21 08:13:52 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381168, encodeId=323c381168d1, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Tue Mar 31 00:14:10 CST 2020, time=2020-03-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1984599, encodeId=a4011984599fc, content=<a href='/topic/show?id=40d93356656' target=_blank style='color:#2F92EE;'>#化疗栓塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33566, encryptionId=40d93356656, topicName=化疗栓塞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Sat Aug 22 06:13:52 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803299, encodeId=08711803299a7, content=<a href='/topic/show?id=e503e52136a' target=_blank style='color:#2F92EE;'>#移植结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75213, encryptionId=e503e52136a, topicName=移植结局)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Thu Jun 11 00:13:52 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978961, encodeId=9c6f19e8961a2, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Jun 19 16:13:52 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863487, encodeId=6e9c186348e4a, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jan 21 08:13:52 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381168, encodeId=323c381168d1, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Tue Mar 31 00:14:10 CST 2020, time=2020-03-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1984599, encodeId=a4011984599fc, content=<a href='/topic/show?id=40d93356656' target=_blank style='color:#2F92EE;'>#化疗栓塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33566, encryptionId=40d93356656, topicName=化疗栓塞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Sat Aug 22 06:13:52 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803299, encodeId=08711803299a7, content=<a href='/topic/show?id=e503e52136a' target=_blank style='color:#2F92EE;'>#移植结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75213, encryptionId=e503e52136a, topicName=移植结局)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Thu Jun 11 00:13:52 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978961, encodeId=9c6f19e8961a2, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Jun 19 16:13:52 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863487, encodeId=6e9c186348e4a, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jan 21 08:13:52 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381168, encodeId=323c381168d1, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Tue Mar 31 00:14:10 CST 2020, time=2020-03-31, status=1, ipAttribution=)]
    2021-01-21 xjy02
  5. [GetPortalCommentsPageByObjectIdResponse(id=1984599, encodeId=a4011984599fc, content=<a href='/topic/show?id=40d93356656' target=_blank style='color:#2F92EE;'>#化疗栓塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33566, encryptionId=40d93356656, topicName=化疗栓塞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Sat Aug 22 06:13:52 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803299, encodeId=08711803299a7, content=<a href='/topic/show?id=e503e52136a' target=_blank style='color:#2F92EE;'>#移植结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75213, encryptionId=e503e52136a, topicName=移植结局)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Thu Jun 11 00:13:52 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978961, encodeId=9c6f19e8961a2, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Jun 19 16:13:52 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863487, encodeId=6e9c186348e4a, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jan 21 08:13:52 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381168, encodeId=323c381168d1, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Tue Mar 31 00:14:10 CST 2020, time=2020-03-31, status=1, ipAttribution=)]
    2020-03-31 一天没事干

    很好的学习机会

    0

相关资讯

PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗肝细胞癌,获得FDA的加速批准

百事美施贵宝公司宣布PD-1单抗Opdivo(nivolumab)联合CTLA-4单抗Yervoy(ipilimumab)治疗肝细胞癌(HCC),获得了FDA的加速批准。

国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功

中国,昆山/上海;美国,加州:2020年01月01日,苏州泽璟生物制药股份有限公司(以下简称“泽璟制药”)今日宣布: ●多纳非尼一线治疗晚期肝细胞癌的III期注册临床研究达到了预设的主要研究终点和统计学要求; ●多纳非尼治疗组患者的总生存期与现有标准治疗索拉非尼对照组相比有显著延长,具有重要的科学意义和临床价值; ●多纳非尼治疗具有更好的安全性,患者耐受性良好。 甲苯磺酸多

超声诊断原发性肝细胞癌右房转移1例

患者女,53岁,丙肝抗体阳性20余年,未监测肝功能和甲胎蛋白,未进行影像学评估。1年前因腹痛1周入院,经腹超声检查:右肝见一大小为8.7 cm×6.3 cm的团状稍低回声,内部回声不均匀,

Brit J Cancer:较高的胆固醇水平与肝细胞癌的较低风险相关

该研究的结果表明他汀类药物对肝癌没有保护作用。

Opdivo+Yervoy二线治疗肝细胞癌被FDA批准

3月11日,百时美施贵宝宣布FDA批准Opdivo(1mg/kg)+Yervoy(3mg/kg)用于治疗既往接受过索拉非尼治疗的肝细胞癌(HCC)患者。

肝细胞癌骶骨转移1例

肝癌位居世界常见恶性肿瘤第6位,其死亡率居第3位,绝大多数为肝细胞癌(HCC)。近年来,肝癌诊断和治疗策略有所改善,患者生存时间得到延长,但5年生存率仍较低(16%),若发生肝外转移,生存率仅为4%。